David Lambeth
Corporate Officer/Principal chez Emory University School of Medicine
Profil
David Lambeth is the founder of Calliditas Therapeutics Suisse SA, which was founded in 2006.
He is currently a Professor at Emory University School of Medicine, where he has been working since 1980.
Dr. Lambeth received a doctorate degree from Duke University.
Postes actifs de David Lambeth
Sociétés | Poste | Début |
---|---|---|
Emory University School of Medicine | Corporate Officer/Principal | 01/01/1980 |
Anciens postes connus de David Lambeth
Sociétés | Poste | Fin |
---|---|---|
Calliditas Therapeutics Suisse SA
Calliditas Therapeutics Suisse SA Pharmaceuticals: GenericHealth Technology Calliditas Therapeutics Suisse SA engages in the development of NOX therapies. Its platform enables the identification of orally available small-molecules that selectively inhibit specific NOX enzymes, which amplify multiple disease processes such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration. The company was founded Chihiro Yabe, Robert A. Clark, David Lambeth, and Karl-Heinz Krause in 2006 and is headquartered in Geneva, Switzerland. | Fondateur | - |
Formation de David Lambeth
Duke University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Entreprise privées | 1 |
---|---|
Calliditas Therapeutics Suisse SA
Calliditas Therapeutics Suisse SA Pharmaceuticals: GenericHealth Technology Calliditas Therapeutics Suisse SA engages in the development of NOX therapies. Its platform enables the identification of orally available small-molecules that selectively inhibit specific NOX enzymes, which amplify multiple disease processes such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration. The company was founded Chihiro Yabe, Robert A. Clark, David Lambeth, and Karl-Heinz Krause in 2006 and is headquartered in Geneva, Switzerland. | Health Technology |